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Abstract
Background: Malignant melanoma is a rare disease in Asia, and knowledge on its characteristics and clinical
outcome in Asian patients is limited. The purpose of this observational study was to determine the clinical
presentation and outcome of patients with melanoma in China.
Methods: A database was prospectively established for the purpose of this analysis. The elements of the
database included basic demographic data of patients and prognosticators previously reported in literature, as
well as follow-up data including clinical outcome after treatment. Medical record of all patients with
pathologically diagnosed malignant melanoma consulted in our center since 2006 were retrieved and reviewed.
No patient was excluded in this study. Statistical analyses including survival and multivariate analyses of factors
associated with survival were respectively performed by Kaplan-Meier method and Cox proportional hazard
model.
Results: A total of 522 consecutive and nonselected cases were evaluated. There were 218 cases (41.8%) of
acral lentiginous melanoma (ALM), 118 (22.6%) of mucosal melanoma (MCM), 103 (19.7%) of nodular
melanoma (NM), 33 (6.3%) of superficial spreading melanoma (SSM), and others were Lentigo maligna
melanoma or unclassifiable disease. The proportion of patients with clinical stage I, II, III, and IV diseases were
6.1%, 55.9%, 25.1%, and 12.8%, respectively. Among the 357 cases of cutaneous melanoma, 234 patients
(65.5%) had ulceration.
The 5-year overall survival rate of all 522 patients was 41.6%, and the median survival time was 3.92 years (95% CI,
3.282 to 4.558). Five-year survival rates of patients with stage I, II, III, and IV diseases were 94.1%, 44.0%, 38.4% and
4.6% respectively (P < 0.001). Multivariate analysis revealed that clinical stage and the ulceration were two
significant prognosticators for OS. In addition, extent of surgery and use of adjuvant therapy were significant
prognosticators for DFS in patients with non-metastatic disease after definitive treatment. Pathological subtype was
not a significant prognostic factor to predict wither OS or DFS.
Conclusions: Prognoses of patients with malignant melanoma diagnosed in China were suboptimal, and most
patients were diagnosed with locally advanced disease (i.e., stage II or above). ALM and MCM are the two most
commonly diagnosed pathological subtypes. Clinical staging and presence of ulceration was significantly
associated with clinical outcome in terms of OS, while treatment strategy including extent of surgery and use of
adjuvant therapy were significant predictors of DFS.
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Malignant melanoma demonstrates a clear demographic
and ethnic disparity, and is a common malignancy in
Western countries among people with light-colored
skin. It has the highest incidence in Queensland,
Australia [1], and is the 5th most commonly diagnosed
cancer in the United States [2]. However, the malig-
nancy is relatively rare among Africans, Hispanics, and
Asians. In addition to the variations demonstrated in
incidences, the Surveillance, Epidemiology, and End
Results (SEER) data from the United States showed that
the clinical characteristics such as pathology, anatomical
origin, and patients’ prognoses differ significantly among
different ethnic groups [3]. Furthermore, although dar-
ker-pigmented populations including Asians may benefit
from protective effect of melanin to ultraviolet radiation,
worse prognoses for non-Caucasian melanoma patients
including a significantly shorter survival time have been
reported [4-6].
Based on the published literatures and reported dispa-
rities, it is reasonable to postulate that malignant mela-
noma diagnosed in non-Caucasian population differs
from those diagnosed in endemic regions. However,
despite the extensively published results from Western
countries, knowledge of melanoma in Asian patients is
scant. Current available literatures for the disease in
Asia are limited to a survey, a small retrospective series,
as well as an epidemiology report from U.S. that
included Asian patients as a minority group [3,7-9].
Clinical evidence for Asian patients especially of large-
scale does not exist due to, at least in part, the rarity of
the disease in this region. As such, the etiology, charac-
teristics, biological behavior, as well as outcome after
treatment are largely unknown for melanoma in Asian
patients. Clearly, additional knowledge on the character-
istics of the disease as well as the outcome after treat-
ment is needed to permit a better understanding of this
highly aggressive and racial specific malignancy.
The aim of this analysis is to bolster the existing but
highly limited literatures on malignant melanoma of
Asian people by documenting the clinical presentation
as well as outcome after active treatment of a relatively
large group of Chinese patients with pathologically con-
firmed malignant melanoma recently treated in our ter-
tiary referral center specialized for the management of
this disease.
Methods
Database Design
A database was prospectively designed for the current
analyses after the approval by the institutional review
board (IRB) of the Beijing Cancer Hospital (BCH)
(Beijing, China) prior to the retrieval and reviewing of
medical records. Elements of the database were based
on published prognostic factors in addition to basic
demographic data, and included characteristics of the
patients (age at diagnosis, gender, and performance sta-
tus), disease (anatomic location, histological subtype,
presence of ulceration, Breslow thickness, and stage),
treatment (modality of treatment, type of surgery and
systemic treatment agents used), and follow-up (time of
disease recurrence/progression, patients’ death, interval
of local control and disease-free survival).
After the designing of the database, medical records of
all patients presented to the Department of Renal
Cancer and Melanoma of BCH with pathologically con-
firmed malignant melanoma were retrieved, reviewed,
and accrued into the database.
Patients and Staging Evaluation
According to the institutional protocol, pretreatment
evaluation of all patients consisted of a complete history
and physical examination, biopsy of the primary or sec-
ondary lesion with pathology study, complete blood
count, serum chemistry, metabolic and liver panels,
thoracic CT scan, and abdominal CT or ultrasound.
Local excision is performed in patients with clinical
stage I cutaneous melanoma without biopsy. Additional
evaluation tests were required for patients who were
accrued into our institutional prospective trials.
The American Joint Committee on Cancer (AJCC)
staging system (6
th edition) was used for either clinical
or pathological staging [10]. For externally referred
patients without pathological evaluation of the Breslow
thickness, clinical stages were determined based on the
available T-category, regional lymph node involvement,
as well as status of distant metastasis.
Data Analysis
The duration of time to locoregional failure or distant
metastasis was measured from the end of treatment for
non-metastatic diseases until documented treatment fail-
ure. The duration of progression-free survival (PFS) in
stage IV patients were from the initiation of any treat-
ment (either systemic or local palliation) until documen-
ted disease progression at any site. The duration of
overall survival (OS) was calculated from the pathologic
diagnosis of melanoma until death or until the date of
the last follow-up visit for patients still alive.
The actuarial local control, disease-free survival (DFS),
PFS, and overall survival rates were calculated by
Kaplan-Meier method [11]. Mantel-Cox log-rank test
stratified by every factor was applied to compare the
Kaplan-Meier curves for survival. Multivariate analyses
of prognosticators for OS, DFS, and PFS were per-
formed using Cox proportional hazard model. Variables
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multivariate analysis.
Results
Between January 2006 and March 2010, a total of 522
consecutive and non-selected cases of malignant mela-
noma with pathologic confirmation were identified and
reviewed. No patient was excluded in this analysis. The
median follow-up time for the entire group of patients
was 16 months (range 1-87 months).
Among the 357 cases of cutaneous melanoma including
acral lentiginous melanoma (ALM), Superficial Spreading
Melanoma (SSM), nodular melanoma (NM), and Lentigo
Maligna Melanoma (LMM), 234 (65.5%) patients had ulcera-
tion in their primary lesion. Characteristics of the patients
and their diseases are detailed in Table 1 and Figure 1.
Treatment
Surgery
All patients with stage I or II disease had undergone
complete resection of their diseases: 95 and 229 cases
received local or extended excision, respectively. Among
the 131 patients with stage III diseases, local excision,
extended excision, and extended excision with regional
nodal dissection were performed in 35, 15, and 76
patients, respectively. All patients achieved complete
resection except for one patient who had positive mar-
gin. In addition, 4 patients did not receive definitive sur-
gery due to patients’ preference or poor performance
status, including 1 who had palliative surgery.
Breslow thickness were measured and recorded in 180
cases of the cutaneous or mucosal disease in patients with
stage I-III diseases after surgery. Measurements of the
thickness of the disease were not performed for the rest of
the group. Sentinel lymph node dissection was not utilized
in the treatment of this group of patients as the majority
had non-cutaneous and more advanced diseases.
Adjuvant Therapy
Among patients had stage I-III diseases, 155 patients
had high-dose IFNa-2b treatment, 109 had adjuvant
chemotherapy with or without radiation, and 2 patients
received adjuvant radiotherapy only. In addition, 184
patients received no adjuvant therapy.
Treatment for Stage IV Disease
All patients with stage IV were treated with systemic
treatment using chemotherapy and or targeted therapy
(on trial basis). One patient with unknown primary had
definitive surgical resection to the solitary metastatic
focus, and 62 cases had palliative surgery. The remain-
ing 5 cases had no surgery.
Clinical staging
Since Breslow thickness was available in 180 of the 455
patients underwent surgery, clinical staging was based
on the available knowledge of T-category, regional nodal
status, and distant metastasis.
Thirty-two patients presented with limited primary
disease (≤ 1.0 mm or ≤ 2.0 mm without ulceration
based on pathology study or clinical evaluation) were
staged as stage I disease. A total of 292 patients with
more advanced T-disease on pathology or physical
examination but no evidence of regional or distant
metastasis were classified as stage II melanoma. And
131 patients with regional lymph adenopathy without
distant metastasis, and 67 patients with distant metas-
tasis were staged as stage III and stage IV diseases,
Table 1 Characteristics of the patients (at diagnosis) and
their diseases
Characteristics No. %
Age at diagnosis (years)
≤ 65 429 82.2
> 65 93 17.8
Gender
Male 276 52.9
Female 246 47.1
Anatomic location
Trunk 53 10.2
Head and neck 39 7.5
Palmoplantar/Subungual 218 41.8
Upper/Lower limb 47 9.0
Mucosal 118 22.6
Unknown 47 9.0
Histology*
LMM 3 0.6
SSM 33 6.3
NM 103 19.7
ALM 218 41.8
MCM 118 22.6
Unclassifiable 47 9.0
Ulceration status
With 234 44.8
Without 123 23.6
Unknown 165 31.6
Breslow thickness (mm)†
≤ 1 27 15.0
1-4‡ 80 44.4
> 4 73 40.6
Stage
I 32 6.1
II 292 55.9
III 131 25.1
IV 67 12.8
* Abbreviation: LMM, lentigo maligna melanoma; ALM, acral lentiginous
melanoma; MCM, Mucosal melanoma; NM, nodular melanoma; SSM,
superficial spreading melanoma.
† Only includes cutaneous melanoma. MCM and unclassifiable type were
excluded.
‡ Includes 4 mm but excludes 1 mm.
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tion for melanoma.
Since close to 40% of all patients had stage III or IV
diseases, and Breslow thickness were recorded in less
than 70% of patients with stage I and II diseases, patho-
logical TNM staging was not established in our
database.
Overall Survival
The 5-year overall survival rate of all 522 patients was
41.6%. The median survival time (MST) was 3.92 years
(95% CI, 3.282 to 4.558) (Figure 2A).
The overall survival rates at 5-years stratified by stages
at diagnosis were 94.1%, 44.0%, 38.4%, and 4.6%, respec-
tively for stages I-IV diseases (Figure 2B) (P < 0.001);
The median survival for stage I patients was not reached
after a median follow-up of 12 months (range: 3-48
months). The median survival time were 4.25 years
(95% CI, 3.557-4.943), 2.83 years (95% CI, 0.595-5.065)
and 1.42 years (95% CI, 1.166-1.674), respectively for
patients with stage II, III, and IV diseases.
The median survival time was 3.58 versus 4.67 years
(P = 0.036) for patients with mucosal melanoma (MCM)
versus non-MCM (Figure 2D). And the 5-year survival
r a t e sf o rM C Ma n dA L Mw e r e2 6 . 8 %v e r s u s5 3 . 9 % ,
respectively (P = 0.003)
No significant difference in OS was observed among
patients with different Breslow thickness of the primary
tumor, although the 5-year OS of patients with disease
≤ 1 mm (92.3%) was higher than the other 2 groups
(48.9% and 50.1% for disease of 1-4 mm and > 4 mm in
thickness) (Figure 2E).
Univariate analyses revealed that histological type,
clinical stage, as well as origin of the disease (mucosa vs.
non-mucosa) were significant prognosticators for overall
survival (Table 2).
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Figure 1 Patient distribution by (A) anatomic location (H-N, head and neck) and (B) histological type (Un, unclassifiable).
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The 5-year disease-free survival (DFS) rate and the med-
ian survival time of 455 patients with stage I-III diseases
were 12.3% (95% CI, 7.4%-17.2%) and 20 months,
respectively.
The histology subtypes, Breslow thickness, presence of
ulceration, location of the primary disease, and age had
no significant value in predicting DFS in univariate ana-
lyses (Table 3).
Univariate analysis of all factors for progression-free
survival (PFS) among patients with stage IV diseases was
not significant.
Prognostic Factors
Potential factors for overall survival (OS) of all patients,
disease-free survival (DFS) for patients with stage I-III
diseases indicated by univariate analyses described above
that demonstrated significance or a trend (P < 0.10)
were further analyzed in multivariate analysis to identify
the independent prognostic factors.
The results of multivariate analysis indicated that
stage at diagnosis and the presence of ulceration were
two significant predictive factors, whereas anatomic
origin of the disease and histological subtype provided
no significant prognostic value for OS. Surgical mod-
ality (extended surgery vs. local excision) and the use
of adjuvant therapy were significant prognosticators
for DFS of patients with stage I-III malignant mela-
noma. Stage of the disease demonstrated a trend in
predicting DFS in non-metastatic melanoma patients
(Table 4).
Discussion
In the current analyses of 522 Asian patients diagnosed
with malignant melanoma, we discovered that histology
subtypes of melanoma diagnosed in Asian patients differ
substantially from those reported in Western popula-
tions. Specifically, the two most commonly diagnosed
subtypes were acral lentiginous melanoma (ALM) and
mucosal melanoma (MCM), which accounted for close
to 65% of all patients collectively. The overall survival of
Asian patients with melanoma was clearly suboptimal:
The 5-year overall and disease-free survival (DFS) rates
and median survival time were 41.6% and 43 months,
and 12.3% and 20 months, respectively. These results
were substantially worse than those observed in the
SEER data from the United States (5-year survival rate
of 91.4%) [12]. However, they were more comparable to
those patients treated for high-risk disease at 37%/1.7
years and 26%/1.98 years, respectively for overall survi-
val and DFS [13].
A number of prognostic factors were analyzed, and
demonstrated that in addition to the two most com-
monly observed prognostic factors emphasized by the
current version of AJCC staging system, i.e., stage of the
disease and the presence of ulceration, other factors
including the pathology subtypes and the origin of the
primary disease were not significant for predicting
7LPH\HDUV
     
&
X
P

6
X
U
Y
L
Y
D
O










A 
MST: 3.92 years (95% CI, 3.282 to 4.558) 
7LPH\HDUV
     
&
X
P

6
X
U
Y
L
Y
D
O










,9FHQVRUHG
,,,FHQVRUHG
,,FHQVRUHG
,FHQVRUHG
,9
,,,
,,
,
6WDJH B 
7LPH\HDUV
     
&
X
P

6
X
U
Y
L
Y
D
O










8QFODVVLILDEOH
FHQVRUHG
0&0FHQVRUHG
/00FHQVRUHG
660FHQVRUHG
10FHQVRUHG
$/0FHQVRUHG
8QFODVVLILDEOH
0&0
/00
660
10
$/0
+LVWRORJLFDOW\SH C 
7LPH\HDUV
     
&
X
P

6
X
U
Y
L
Y
D
O










!PPF H QV RUH G
PPFHQVRUHG
 PPF H QV R UH G
!PP
PP
 PP
%UHVORZWKLFNQHVV E 
7LPH\HDUV
     
&
X
P

6
X
U
Y
L
Y
D
O










QRQ0&0FHQVRUHG
0&0FHQVRUHG
QRQ0&0
0&0
0&0YQRQ0&0 D 
7LPH\HDUV
     
&
X
P

6
X
U
Y
L
Y
D
O










ZLWKFHQVRUHG
ZLWKRXWFHQVRUHG
ZLWK
ZLWKRXW
8OFHUDWLRQ F 
Figure 2 Kaplan-Meier analyses of overall survival (OS) for the entire group of patients according to different stratums by prognostic
factors (overall comparison was administered by Mantel-Cox log-rank test). Overall survival (A), OS based on stage (P < .001) (B), histology
(P < .001) (C), MCM and non-MCM patients (P = .036) (D), Breslow thickness (P = .29) (E), and Ulceration status (P = .08) (F).
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Page 5 of 10overall survival (OS) in multivariate analyses. Neverthe-
less, the use of adjuvant therapy and extent of surgery
were found to be significant factors, and stage at diagno-
sis showed a clear trend, in predicting the disease-free
survival (DFS) after treatment for patients with non-
metastatic melanoma.
Stage and the extent of the primary disease (i.e., Bre-
slow thickness) have been repeatedly confirmed to be
the most important prognostic indicators for melanoma
[3,14,15]. However, most evidences presented in the lit-
eratures were originated in endemic regions particularly
Western countries, and the most commonly diagnosed
subtype of malignant melanoma is superficial spreading
melanoma (SMM). Due to the high prevalence of the
disease, knowledge on diagnosis and screening is readily
available and diagnoses are usually made in relatively
earlier stages. The applicability of the AJCC/UICC TNM
staging system in melanoma patients from non-endemic
regions particularly for histological subtypes rarely
observed in endemic regions has not been adequately
addressed. Although malignant melanoma is a relatively
rare disease in Asia, the incidence of melanoma is
increasing. In a nationwide survey of 4495 cases of mel-
anoma from 1992 to 1998 in Japan, the incidence of the
disease increased 5-folds [16]. A similar pattern was
observed in the metropolitan areas in China, although
systemically established tumor registry is lacking.
The lack of knowledge of the disease in Asian patients
clearly hampers the understanding thus the development
of proper treatment strategy in this particular group of
patients, as well as further research for more effective
diagnosis and treatment. Therefore, we consider our
finding important as the results confirmed the applic-
ability of the updated AJCC staging to Asian patients
with different subtypes of malignant melanoma. Both
univariate and multivariate analyses of our data showed
that clinical staging as well as presence of ulceration
were two significant prognosticator for overall survival,
in consistent with those reported in endemic regions
including United States and Australia, regardless of
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Figure 3 Kaplan-Meier analyses of disease-free survival (DFS) of 450 patients with stage I-III melanoma received definitive therapy
according to different stratums by prognostic factors (overall comparison was performed by Mantel-Cox log-rank test): (A) Male vs.
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Page 6 of 10histological subtypes [10-18]. In addition, a trend was
demonstrated in our series for clinical staging in pre-
dicting DFS for patients with non-metastatic disease.
Among the five histological types in our series, ALM
is the most common type in China accounting for
nearly half of all patients, while the sum of NM, SMM
and LMM is less than half of ALM. These results are
consistent with the data from other Asian countries
[7-9], but differed from those reported in the endemic
regions where SSM, NM, LMM, and ALM account for
> 70%, 15%, 13%, and 2-3%, respectively [3,15,18]. It is
suggested that racial status play a key role in worldwide
proportion of different histological types. In 1976, RJ
Reed first described ALM and noted that this type of
melanoma was the most common expression of mela-
noma in blacks [20]. Lately, ALM was found to be more
commonly diagnosed in Asians and African Americans.
In addition, African-Americans were found to have sig-
nificantly shorter survival time as compared to their
Caucasian counterparts in the United States [5]. Results
Table 2 Univariate analyses of prognostic factors for OS
in patients with malignant melanoma
Factors Median OS (y) P value
Histological type
ALM 5.330 < 0.001
NM 4.080
SSM 4.670
MCM 3.580
Unclassifiable 2.000
MCM vs. non-MCM
MCM 3.580 0.036
Non-MCM 4.670
Primary location
Trunk 4.670 < 0.001
H&N Not reached
Palmoplantar/Subungual 10.830
Upper/Lower limb 4.000
Mucosal 3.580
Unknown 2.000
Stage
I not reached < 0.001
II 4.250
III 2.830
IV 1.420
Gender
Male 3.830 0.715
Female 3.920
Age
≤ 65 y 3.750 0.127
> 65 y not reached
Ulceration
with 4.000 0.080
without not reached
Breslow thickness*
≤ 1 mm 0.290
1-4 mm 4.080
> 4 mm 4.000
*Limited to 180 cases with recorded Breslow thickness.
Table 3 Univariate analyses of prognostic factors for DFS
in patients with malignant melanoma
Factors Median DFS
(months)
P value
Histological type
ALM 20.0 0.716
NM 20.0
SSM 28.0
LMM 16.0
MCM 17.0
Unclassifiable 16.0
Primary location
Trunk 25.0 0.721
H&N 16.0
Palmoplantar/Subungual 20.0
Upper/Lower limb 21.0
Mucosal 17.0
Unkown 16.0
Stage
I 44.0 < 0.001
II 21.0
III 13.0
Gender
Male 16.0 0.035
Female 22.0
Age
≤ 65 y 20.0 0.709
> 65 y 20.0
Surgery
Local resection 15.0 < 0.001
Extended resection 24.0
Ext. resection w/nodal
dissection
13.0
Adjuvant therapy
None 13.0 < 0.001
Chemotherapy 20.0
Chemoradiation 29.0
IFN Not reached
Radiation 23.0
Ulceration
with 20.0 0.488
without 20.0
Breslow thickness*
≤ 1 mm 38.0 0.178
1-4 mm 21.0
> 4 mm 13.0
*Limited to 180 cases with recorded Breslow thickness.
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possess worse prognosis as compared to other types of
melanoma such as SSM [9,19,21]. In the current series,
we found that histological subtype was a significant
prognosticator for overall survival in univariate analysis.
However, when stage and presence of ulceration was
added, multivariate analyses revealed that histological
subtypes per se was not a significant predictor for OS.
One of the potential reasons for this discovery was that
ALM might have higher incidence of non-cutaneous
(e.g., mucosal lesions) thereby a later stage presentation
at diagnosis as compared to cutaneous SSM in endemic
regions. Whereas in China, stage III and IV diseases
were the majority thus the confounding effect of late
diagnosis of ALM does not exist. Since the distribution
of various subtypes of melanoma in our series was
uneven, directly comparison for clinical presentation
and outcome between ALM versus SSM, as well as
other pathologies were not feasible.
As far as we know, this is the first large-scale observa-
tional study for malignant melanoma in Asian patients.
Few reports have been published to address the epide-
miology in Asia. In an updated survey from Japan
published by Ishihara et al, malignant melanoma demon-
strated a clear increasing incidence [22]. Furthermore,
ALM and nodular melanoma (NM) were the cost com-
mon types and collectively accounted for close to 2/3 of
all melanoma diagnosed in Japan. These data collide well
with our results and those observed in Taiwan [9]. How-
ever, evaluation of the effects of certain treatment modal-
ity in the Japanese survey such as prophylactic lymph
node dissection and adjuvant systemic therapy were
inconclusive, and detailed knowledge on treatment as
well as outcome is lacking due to the nature of a survey.
On the other hand, our data demonstrated a clear benefit
of adjuvant therapy, and suggested an efficacy of aggres-
sive treatment in melanoma of Asian patients.
One of the prognostic factors that have not been
addressed previously in literature is the mucosal origin
of the primary. Mendenhall et al. reported the head and
neck mucosal melanoma to be a rare entity comprising
less than 1% for all Western melanomas. The likelihood
of local recurrence after resection is approximately 50%
with 5-year survival rates ranging from 20% to 50% [23].
Since mucosal melanoma occurred in 22.6% of all cases
in our series, it was analyzed against non-MCM as a
prognostic factor for OS and was found to be significant
(P = 0.036). The primary lesions of MCM varied from
nasal cavity, paranasal sinuses, oral cavity, choroids, to
cervix and even vagina (not shown in this article). The
features of occult onset, early recurrence after resection,
and present at an advanced stage even with metastasis
contribute to the poor survival of MCM.
Although our study represented the largest clinical
series and analyses of malignant melanoma in Asia, a
number of limitations need to be addressed. Firstly, the
database for the current series was prospectively
designed and prepared based on the characteristics and
factors published in the literature; however, the observa-
tional nature of the analysis precluded exhaustive record
keeping for all the factors in all cases. As a cancer cen-
ter specialized in the management of malignant mela-
noma, referral after surgical resection of the disease to
our center is not uncommon. Malignant melanoma is
among one of the rarest cancers in China, thus knowl-
edge on proper diagnosis and treatment may not be
readily available among the primary care physicians. As
such, a number of parameters of the disease including
Breslow thickness and the presence of ulceration were
not recorded exhaustively. Thickness is the primary
determinant of T-category in AJCC staging system of
melanoma and in the 6th edition of AJCC in 2002,
thickness thresholds were revised to 1.0, 2.0 and 4.0 mm
due to a large statistic result of 17,600 patients [10,18].
Although our data revealed the 5-year OS of patients
with thickness ≤ 1 mm (92.3%) was substantially higher
than those of 1-4 mm (48.9%) and > 4 mm (50.1%), the
incomplete data especially the extent of the primary dis-
e a s em a yb et h ek e yr e a s o nt h a tB r e s l o wt h i c k n e s sw a s
insignificant in predicting the overall survival in multi-
variate analyses. Another potential reason might be the
advanced stage at presentation, i.e., the majority of
patients had lymph node metastasis and distant
metastasis.
Since malignant melanoma is a relatively rare disease in
Asia, the majority of patients initiated their treatment in
our center were accrued into clinical trials, especially
those with more advanced, i.e., stage II-IV, diseases. The
effect of the heterogeneous treatment modalities used in
clinical trials may also affect the treatment outcome. The
results of a recently published prospective randomized
trial showed that adjuvant radiation therapy to the regio-
nal lymph nodes significantly improved DFS in patients
with high-risk melanoma after Lymphadenectomy [24].
In addition, adjuvant systemic treatment with interferon
in patients with advanced disease is controversial, based
on results of systemic reviews and meta-analyses [25,26].
Table 4 Multivariate analyses of prognostic factors for OS
and DFS
Overall Survival Disease-Free Survival*
Prognosticators P Value Prognosticators P Value
Stage < 0.001 Stage 0.10
Ulceration 0.043 Surgical Technique 0.004
Histological Type 0.410 Adjuvant Therapy < 0.001
Anatomic Region 0.251 Gender 0.351
* DFS in non-metastatic patients who received definitive surgery.
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endemic regions and ALM and MCM melanoma are
usually not a substantial component of the samples stu-
died. Our analyses showed that adjuvant treatments and
types of surgery in patients with non-metastatic disease
might be a significant prognosticator for DFS. These
findings appeared similar to those demonstrated in the
literature based on other subtypes of melanoma. How-
ever, the selection of type of surgery and adjuvant treat-
ment largely depended on the extent of disease, i.e.
clinical staging in our series. The observation of an
improved DFS but not OS by more extended surgical
subtypes questioned whether improved local control
could translate to survival in the more commonly diag-
nosed melanoma subtypes in Asia. Similar questions also
need to be answered for the use of aggressive local and/
or systemic adjuvant therapy. Clearly, more effective
treatment is clearly needed. Unfortunately, the heteroge-
neity of our adjuvant treatment strategy precluded
detailed and meaningful analyses of the efficacy of indivi-
dual types of therapy.
Patients with stage IV malignant melanoma are
usually treated with systemic biological and/or che-
motherapy. However, treatment for metastatic mela-
noma has always been a challenge, and aggressive
treatment including combining chemotherapy and
immunotherapy failed to show additive efficacy [27].
Furthermore, targeted therapy such as sorafenib or bev-
acizumab has been the focus of study for metastatic dis-
ease; however, most of the clinical trials revealed
moderate or limited efficacy [28-30]. Currently, only one
targeted agent demonstrated significant efficacy when
used alone [31]. In our institute, stage IV melanoma
patients are encouraged to participate clinical trial(s),
and most of the 61 patients with stage IV disease were
accrued in prospective studies including a combined
molecular targeted therapy regimen. The outcomes of
these clinical trials are pending.
Although the current series presented the largest clini-
cal data in Asia, epidemiology and etiology of malignant
melanoma diagnosed in China were not the focus of the
study. One of the interesting issues that await further
research is the influence of sunlight to the incidence of
cutaneous melanoma (not including ALM) in China.
Currently there is no epidemiologic research reported
from Asia that has addressed the cause-effect association
between sun exposure and cutaneous melanoma.
Although the protective effect of melanin in Asian
population is well known, the anecdotal observation of
the increasing incidence in China may be associated
with the lifestyle changes. In addition, as a tertiary
cancer institute specialized in melanoma treatment, the
number of more advanced disease seen in our center
may be overestimated. As such, a regional statistical
investigation is needed and is currently under active
planning to address the epidemiology of malignant in
melanoma more effectively.
Conclusions
Most malignant melanoma patients in China were
diagnosed with locally advanced disease (i.e., stage II
or above), and their prognoses were suboptimal. ALM
and MCM are the two most commonly diagnosed
pathological subtypes of malignant melanoma in
China. Clinical staging and presence of ulceration was
significantly associated with clinical outcome in terms
of OS, while treatment strategy including extent of
surgery and use of adjuvant therapy were significant
predictors of DFS.
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